- Details
- Description
-
Packaging Size200mg*34t,400mg*17t,800co-pack(800mg*16t&200mg*2t)
-
Strength200mg,400mg,800mg
-
CompositonFavipiravir
-
TreatmentCOVID-19、Influenza
-
Formtablet
-
BrandFabiflu
-
Quantity Unitquantity unit
-
ManufacturerGlenmark
Favipiravir: A new and emerging antiviral option in COVID-19.
Discovered by Toyama Chemical Co., Ltd. in Japan, favipiravir is a modified pyrazine analog that was initially approved for therapeutic use in resistant cases of influenza. The antiviral targets RNA-dependent RNA polymerase (RdRp) enzymes, which are necessary for the transcription and replication of viral genomes. Not only does favipiravir inhibit replication of influenza A and B, but the drug has shown promise in the treatment of avian influenza, and may be an alternative option for influenza strains that are resistant to neuramidase inhibitors. Favipiravir has been investigated for the treatment of life-threatening pathogens such as Ebola virus, Lassa virus, and now COVID-19.
Reference resources:
